Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORMP Oramed Pharmaceuticals

Trading 02-06 14:05:15 EST

3.39

+0.15

+4.63%

High3.39	Low3.22	Vol100.91K
Open3.28	D1 Closing3.24	Amplitude5.25%
Mkt Cap134.93M	Tradable Cap110.37M	Total Shares39.80M
T/O334.19K	T/O Rate0.31%	Tradable Shares32.56M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORMP","market":"US","secType":"STK","nameCN":"Oramed Pharmaceuticals","latestPrice":3.39,"timestamp":1770404671293,"preClose":3.24,"halted":0,"volume":100908,"delay":0,"changeRate":0.046296296296296266,"floatShares":32556743,"shares":39802455,"eps":1.026987,"marketStatus":"Trading","change":0.15,"latestTime":"02-06 14:05:15 EST","open":3.28,"high":3.39,"low":3.22,"amount":334187.9822088,"amplitude":0.052469,"askPrice":3.39,"askSize":200,"bidPrice":3.37,"bidSize":100,"shortable":3,"etf":0,"ttmEps":1.026987,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770411600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.24,"preHourTrading":{"tag":"盘前","latestPrice":3.27,"preClose":3.24,"latestTime":"08:44 EST","volume":24,"amount":78.3599976,"timestamp":1770385457045,"change":0.03,"changeRate":0.009259,"amplitude":0.037037},"postHourTrading":{"tag":"盘后","latestPrice":3.1,"preClose":3.24,"latestTime":"19:54 EST","volume":28331,"amount":86778.9486,"timestamp":1770339266495,"change":-0.14,"changeRate":-0.04321,"amplitude":0.089506},"volumeRatio":0.866501,"impliedVol":1.4227,"impliedVolPercentile":0.9522},"requestUrl":"/m/hq/s/ORMP/wiki","defaultTab":"wiki","newsList":[{"id":"2603642601","title":"Oramed Transfers Oral Drug Platform to Lifeward in Strategic Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2603642601","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603642601?lang=en_us&edition=fundamental","pubTime":"2026-01-15 05:32","pubTimestamp":1768426325,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has entered into binding agreements with Lifeward Ltd. to transfer its proprietary Protein Oral Drug  delivery technology to Lifeward. As part of the transaction, Oramed will receive a 49.9% beneficial ownership interest in Lifeward, along with warrants. Oramed will continue to manage and fund the upcoming clinical trial for the oral delivery platform. In addition, Oramed will receive 4% of net sales from Lifeward’s ReWalk franchise for up to 10 years. Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, and has generated $26 million in revenue from its FDA-approved ReWalk and AlterG products in the last four quarters. The transaction is expected to advance the oral insulin program and further diversify Lifeward’s biomedical innovation portfolio.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL8XQX0R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP","BK4604","BK4082","LFWD"],"gpt_icon":0},{"id":"2603684341","title":"Lifeward Ltd - Receives up to $47 Mln Investment From Oramed and Another Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684341?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2603684305","title":"Lifeward Ltd - Oramed to Buy up to 49.99% Equity in Lifeward","url":"https://stock-news.laohu8.com/highlight/detail?id=2603684305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603684305?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2603681228","title":"Lifeward Enters Transformative Strategic Investment and Partnership Agreement With Oramed to Create a Diversified Biomedical Innovation Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681228?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2603372684","title":"Lifeward Ltd - Buys Oramed's Pod Technology for Biotech Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2603372684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603372684?lang=en_us&edition=fundamental","pubTime":"2026-01-13 21:00","pubTimestamp":1768309205,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA4QQDGG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2603681489","title":"BRIEF-Oramed And Lifeward Announce Strategic Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681489","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681489?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:59","pubTimestamp":1768309198,"startTime":"0","endTime":"0","summary":"BRIEF-Oramed And Lifeward Announce Strategic TransactionJan 13 (Reuters) - Lifeward Ltd 2RW.MU:ORAMED AND LIFEWARD ANNOUNCE STRATEGIC TRANSACTIONORAMED PHARMACEUTICALS INC - TO RECEIVE 49.9% OWNERSHIP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2603868112","title":"Oramed Invests $9 Million in Lifeward and Transfers Oral Drug Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2603868112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603868112?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309096,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has entered into a strategic transaction with Lifeward Ltd., transferring its proprietary Protein Oral Drug  delivery technology to Lifeward. As part of the agreement, Oramed will obtain a 49.9% beneficial ownership interest in Lifeward and will invest $9 million in a $10 million senior secured convertible note, with the potential to significantly increase its stake through additional milestone-based investments and warrant exercises. Oramed will also fund and manage an anticipated upcoming clinical trial for the technology, marking a significant expansion of its involvement in oral drug delivery innovation and medical robotics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. publi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL8BZHP8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4604","LFWD","ORMP","BK4007"],"gpt_icon":0},{"id":"2603811496","title":"Oramed Pharmaceuticals Inc - Lifeward to Issue $10 Mln Convertible Notes","url":"https://stock-news.laohu8.com/highlight/detail?id=2603811496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603811496?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2603681409","title":"Oramed Pharmaceuticals Inc - Will Receive 4% on Net Sales of Rewalk Franchise for up to 10 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681409?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2603681146","title":"Oramed Pharmaceuticals Inc - Mark Grant to Lead Combined Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681146?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2603681141","title":"Oramed Pharmaceuticals Inc - to Receive 49.9% Ownership in Lifeward","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681141?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2603144681","title":"Oramed and Lifeward Announce Strategic Transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2603144681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603144681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:58","pubTimestamp":1768309086,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YE104:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2601806966","title":"Oramed Pharmaceuticals Inc. announces $0.25 per share dividend totaling approximately $10.5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806966","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806966?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:55","pubTimestamp":1767794116,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. has announced a cash dividend of $0.25 per share, approved by its Board of Directors. The total distribution is expected to be approximately $10.5 million based on the current number of shares outstanding. No dividend was distributed the previous year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL3YwF3X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2601952806","title":"Oramed Pharmaceuticals Inc: Also Maintains Its Warrant Position as Well as a Nine-Year Royalty Interest in Scilex Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2601952806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601952806?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:55","pubTimestamp":1767794105,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y802E:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"gpt_icon":0},{"id":"2601806954","title":"Oramed Pharmaceuticals Inc - Retains $27 Mln Note and $12 Mln Convertible Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806954?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:55","pubTimestamp":1767794105,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y802E:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2601806997","title":"Press Release: Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2601806997","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601806997?lang=en_us&edition=fundamental","pubTime":"2026-01-07 21:55","pubTimestamp":1767794100,"startTime":"0","endTime":"0","summary":"Payment Closes Out Option Agreement Obligations; Oramed Retains $39 Million Outstanding debt, Convertible Debt, Warrants, and an Ongoing Royalty Interest. NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Oramed Pharmaceuticals Inc.   today announced it has received an $18 million payment from Scilex Holdings Inc., representing full satisfaction of obligations under the Option Agreement. This payment brings Oramed's current returns to $118 million on its original $99.5 million Scilex investment, with additional returns expected from the remaining convertible notes, warrants, and royalties.Oramed retains a $27 million note and a $12 million convertible note with Scilex, convertible at Oramed's option into Scilex equity at $36 per share. If not converted, the note will be repaid by Scilex in quarterly installments through October 2026. Oramed also maintains its warrant position as well as a nine-year royalty interest in Scilex products.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4099","BK4588","BK4604","ORMP","BK4585","TM","03160","BK4007"],"gpt_icon":0},{"id":"2600019407","title":"Oramed Pharmaceuticals Director Leonard Sank Resigns After 18 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2600019407","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600019407?lang=en_us&edition=fundamental","pubTime":"2026-01-01 05:31","pubTimestamp":1767216671,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc. announced that Leonard Sank will resign from its board of directors, effective January 1, 2026, after 18 years of service. The company stated that the resignation was not due to any disagreement regarding company operations, policies, or practices.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 31, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL5HNnVF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0},{"id":"2595127907","title":"Scilex Completes $27 Million Repurchase of Oramed Penny Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2595127907","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595127907?lang=en_us&edition=fundamental","pubTime":"2025-12-31 04:38","pubTimestamp":1767127082,"startTime":"0","endTime":"0","summary":"Scilex Holding Company has completed the repurchase of warrants previously issued to Oramed Pharmaceuticals Inc. The company exercised its option to repurchase a total of 6,500,000 \"Penny Warrants\"—warrants to purchase Scilex common stock at $0.01 per share—in two tranches for an aggregate purchase price of $27 million. The first tranche, totaling $13 million, was completed in September 2025, and the second tranche, amounting to $14 million, was finalized on December 30, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scilex Holding Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251230:nNDL5k4Clb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SCLX","ORMP","BK4007"],"gpt_icon":0},{"id":"2585105161","title":"Oramed Pharmaceuticals' (NASDAQ:ORMP) Profits May Be Overstating Its True Earnings Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2585105161","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585105161?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:08","pubTimestamp":1763723323,"startTime":"0","endTime":"0","summary":"Investors appear disappointed with Oramed Pharmaceuticals Inc.'s ( NASDAQ:ORMP ) recent earnings, despite the decent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ormp/oramed-pharmaceuticals/news/oramed-pharmaceuticals-nasdaqormp-profits-may-be-overstating","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ormp/oramed-pharmaceuticals/news/oramed-pharmaceuticals-nasdaqormp-profits-may-be-overstating","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":[".IXIC","ORMP"],"gpt_icon":0},{"id":"2584629282","title":"BRIEF-Oramed Reports Fiscal Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629282","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629282?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:02","pubTimestamp":1763388176,"startTime":"0","endTime":"0","summary":"BRIEF-Oramed Reports Fiscal Third Quarter 2025 Financial ResultsOramed Pharmaceuticals Inc ORMP.O:ORAMED REPORTS FISCAL THIRD QUARTER 2025 FINANCIAL RESULTSSource text: ID:nPnb1nV5MaFurther company coverage: ORMP.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nTUA2XSQWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oramed.com","stockEarnings":[{"period":"1week","weight":-0.0526},{"period":"1month","weight":0.0554},{"period":"3month","weight":0.4795},{"period":"6month","weight":0.5502},{"period":"1year","weight":0.4795},{"period":"ytd","weight":0.1368}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.018109},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.022099},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.013462},{"month":4,"riseRate":0.769231,"avgChangeRate":0.017276},{"month":5,"riseRate":0.538462,"avgChangeRate":0.041552},{"month":6,"riseRate":0.384615,"avgChangeRate":0.018782},{"month":7,"riseRate":0.461538,"avgChangeRate":0.04461},{"month":8,"riseRate":0.384615,"avgChangeRate":0.00834},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.048853},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.028699},{"month":11,"riseRate":0.538462,"avgChangeRate":0.137309},{"month":12,"riseRate":0.384615,"avgChangeRate":0.051334}],"exchange":"NASDAQ","name":"Oramed Pharmaceuticals","nameEN":"Oramed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oramed Pharmaceuticals,ORMP,Oramed Pharmaceuticals股票,Oramed Pharmaceuticals股票老虎,Oramed Pharmaceuticals股票老虎国际,Oramed Pharmaceuticals行情,Oramed Pharmaceuticals股票行情,Oramed Pharmaceuticals股价,Oramed Pharmaceuticals股市,Oramed Pharmaceuticals股票价格,Oramed Pharmaceuticals股票交易,Oramed Pharmaceuticals股票购买,Oramed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction